Charles B Nguyen, Melissa A Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y Feng, Emmanuel S Antonarakis, Rana R McKay, Russell K Pachynski, Jingsong Zhang, Zachery R Reichert, Phillip L Palmbos, Megan E V Caram, Ulka N Vaishampayan, Elisabeth I Heath, Alexander C Hopkins, Marcin P Cieslik, Yi-Mi Wu, Dan Robinson, Veerabhadran Baladandayuthapani, Arul M Chinnaiyan, Ajjai S Alva
PURPOSE: CDK12 inactivation in metastatic castration-resistant prostate cancer (mCRPC) may predict immunotherapy responses. This phase 2 trial evaluated the efficacy of immune checkpoint inhibitor (ICI) therapy in patients with CDK12-altered mCRPC. PATIENTS AND METHODS: Eligible patients had mCRPC with deleterious CDK12 alterations and any prior therapies except ICI. Cohort A received ipilimumab (1 mg/kg) with nivolumab (3 mg/kg) every 3 weeks for up to 4 cycles, followed by nivolumab 480 mg every 4 weeks...
May 24, 2024: Clinical Cancer Research